For people with certain BRCA mutations, activating the immune system could be promising treatment — ScienceDaily

Treatments that harness the immune system to fight cancer have greatly improved outcomes for some people with cancer. Scientists are learning more about why some people respond much better than others to these drugs.

One major factor is something called tumor mutation burden (TMB) — the number of DNA changes a tumor has. Studies from researchers at Memorial Sloan Kettering and elsewhere have shown that tumors with high TMB tend to respond better to immune checkpoint inhibitors. In 2017, the US Food and Drug Administration approved the checkpoint inhibitor pembrolizumab (Keytruda®) for the treatment of tumors with a type of genetic defect called mismatch repair (MMR) deficiency.

MMR is one of several DNA repair pathways that cells use to fix mistakes in DNA. Mutations in this pathway lead to faulty DNA repair and therefore to higher TMB. Next to MMR, the most commonly mutated DNA repair pathway is called homologous

Read More

More evidence that cellular ‘death by iron’ could be promising avenue of cancer treatment — ScienceDaily

If there is a silver lining in cancer’s chaotic biology, it’s that the same traits that give cancer cells a growth advantage often present opportunities for sabotaging them.

That’s the central idea behind a new research paper published November 23 in Proceedings of the National Academy of Sciences (PNAS) by Xuejun Jiang, a cell biologist in the Sloan Kettering Institute, and Craig Thompson, President and CEO of Memorial Sloan Kettering. They found that cancer cells often exhibit metabolic changes that make them vulnerable to a particular type of cell death called ferroptosis.

Ferroptosis — literally, death by iron — is often triggered by oxidative stress, the buildup in cells of free radicals and other corrosive chemicals that are byproducts of using oxygen to burn fuel for energy. But many cancer cells, which need abundant amounts of energy to grow and divide, have found a way around this problem.

“Genetic mutations

Read More

The 7 Most Promising Government Led AI Solutions

As the 21st century rages on, success and failure of nations depends not only on their citizenry and governmental leadership, but heavily on the technological visions that countries embrace. If a nation takes the approach of sitting back or standing still as automation and Artificial Intelligence advance at ever increasing rates, that nation is destined to be left behind. However, if a country embraces AI and dedicates significant resources and top minds to ethical implementation, that country is destined to be a leader for decades to come.

Recently Steve Mills, Chief AI Ethics Officer & Leader for Artificial Intelligence in the Public Sector, and Partner at Boston Consulting Group said quite eloquently “AI has become table stages for global national economic and technological competitiveness. This goes beyond nations capturing a piece of the large and rapidly growing AI market. AI is poised

Read More

Perimeter Medical Imaging AI Recognized as One of the “10 Most Promising Companies” at the Texas Life Science Forum

TORONTO, ON and DALLAS, TX / ACCESSWIRE / November 19, 2020 / Perimeter Medical Imaging AI, Inc. (TSXV:PINK; FSE:4PC) (“Perimeter” or the “Company”), a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need, was recognized as one of the 10 Most Promising Companies at the 2020 Texas Life Science Forum co-hosted by the Rice Alliance for Technology and Entrepreneurship and BioHouston from November 10 to 12, 2020. The companies were chosen by industry experts and investors.

Jeremy Sobotta, Perimeter’s Chief Executive Officer, commented, “We are pleased and honoured to be recognized as one of the most promising companies at the recent Texas Life Science Forum alongside the many other innovative medtech, digital health, and pharmaceutical companies that participated virtually this year. In the near-term, we are committed to bringing our novel medical imaging technology to market with

Read More

DOD Has Promising Tech. Now It’s Time to Scale It Up, Officials Say

In August, Michèle Flournoy, widely believed to be President-elect Joe Biden’s top pick to lead the Defense Department, put the spotlight on emerging technology when she told the Aspen Security Forum she believes future Defense Department budgets are likely to flatline, necessitating “big bets” on innovative technologies.  

Regardless of whether Flournoy’s budget prediction comes true, Defense officials and experts say moving technology development beyond incubation to adoption at scale should be a priority over the next several years. 

Diem Salmon, an adjunct senior fellow at the Center for New American Security, former Senate Armed Services Committee budget director and current defense contractor, told Nextgov DOD should start taking larger bets to scale up a handful of specific capabilities. 

“There’s been enough work done over the past couple of years that there are certain things that are ready to scale or ready to get pulled into that program of record status,

Read More

Promising MS drug may worsen disease — ScienceDaily

A drug that has shown promise for treating multiple sclerosis may actually make the debilitating disease worse, new research from the University of Virginia School of Medicine suggests.

The drug has not yet made it to human trials for MS, but the UVA scientists are warning their fellow researchers to proceed extremely cautiously. In addition to worsening the disease in mouse models, the drug also had unintended, off-target effects, they report.

“It was not at all what we expected,” said MS researcher Alban Gaultier, PhD, of UVA’s Department of Neuroscience and its Center for Brain Immunology and Glia (BIG). “The take-home message is that we should be very careful and do more fundamental research before we propose to take this to clinical trials.”

About Multiple Sclerosis

Multiple sclerosis is a debilitating autoimmune disease that affects an estimated 1 million Americans. The disease causes the body’s immune system to destroy myelin,

Read More

Stock futures flat in overnight trading following a record-setting rally on promising vaccine news

People walk by the New York Stock Exchange.

Spencer Platt | Getty Images

Stock futures held steady in overnight trading on Monday following a record-setting rally sparked by promising news on a coronavirus vaccine.

Futures on the Dow Jones Industrial Average dipped 20 points. S&P 500 futures fell 0.1% and Nasdaq 100 futures also traded 0.1% lower.

The overnight action came after a strong rally on Wall Street that saw the Dow and the S&P 500 hit new intraday record highs. The 30-stock average rallied more than 800 points, posting its biggest one-day gain since June 5. It surged more than 1,600 points at one point before the weakness in the tech sector put pressure on the broader market. The S&P 500 gained 1.2%.

U.S. pharmaceutical giant Pfizer and German biotech firm BioNTech announced Monday their coronavirus vaccine was more than 90% effective in preventing Covid-19. The news sent travel

Read More

What Apple Is Promising With The New MacBooks And Its Smartphone-Derived Silicon

As I reported in June, Apple announced at its WWDC that it is moving the Mac lineup of PCs from Intel processors to its own home-grown mobile SoCs. The company says it will manage a multi-year transition from Intel-based systems over two years, and it will leverage its Bionic line of IP for its new designs. This Tuesday, Apple will announce new Macs with the new smartphone-derived processors, and I thought it made sense to review what the company said it would deliver during WWDC to prepare for the event. I watched the event a few times and even transcribed the contents. Here are my highlights of what Apple promised.

Claim #1: overall “whole new level of performance”

Apple said that for the new Macs, by using its smartphone-derived Apple silicon, “the first thing this will do is give them a whole new level

Read More

Smartphone maker taking over Genesis Center, promising hundreds of jobs and $100 million in investment | Northwest Indiana Business Headlines

Saied said the project is fully financed and construction could begin in 90 days. It will take nine months to a year to build the plant, which will be expandable. Akyumen also might consider future manufacturing operations elsewhere in the city.

He expects the company can create more than 2,000 jobs in three to five years and potentially more if all the carriers and distributors in the United States use its devices. Production worker jobs will pay at least $35,000 a year. The company also will employ people in higher-paying “science, technology and mathematics” jobs. 

Gary will work with WorkOne to train residents for the positions, aiming to line up job opportunities for as many Gary residents as possible.

“Our company is not about creating sweatshop jobs in the United States,” Saied said. “It will create smart jobs.”

The plant will be up and running by spring of 2022, but

Read More

Agent shows promising results in nonhuman primates — ScienceDaily

Researchers have validated a new radiolabeled molecule that can be used with imaging tests to accurately detect and characterize brain injury. The team, led by investigators at Massachusetts General Hospital (MGH), recently received clearance from the U.S. Food and Drug Administration (FDA) to initiate a first-in-human study with the strategy.

As described in the Journal of Cerebral Blood Flow & Metabolism, the novel tracer, called [18F]3F4AP, is designed to bind to potassium channels and is radiolabeled so it can be visualized through positron emission tomography (PET) imaging. Potassium channels in the brain’s neurons become exposed when the neurons become demyelinated, or lose their protective coating (called myelin), which occurs with a variety of neurodegenerative conditions.

“Because potassium channels increase in expression and accessibility upon demyelination, this tracer holds promise for imaging multiple sclerosis and other diseases such as traumatic brain and spinal cord injuries, stroke and Alzheimer’s

Read More